DiscGenics treats 1st patients in degenerative disc disease cell therapy trial — 3 insights

Alan Condon -   Print  |

Discgenics treated the first patients in its clinical trial of intervertebral disc tissue for mild to moderate degenerative disc disease in Japan, reports Biospectrum Asia.

Three insights:

1. The double-blinded trial is evaluating the efficacy of IDCT at two dosage levels in participants with single-level symptomatic lumbar degenerative disc disease.

2. IDCT is an allogeneic, non-invasive cell therapy that is injected into the painful disc percutaneously.

3. It uses biomedically engineered progenitor cells — known as discogenic cells — that are derived from intervertebral disc tissue to look for a regenerative solution to degenerative disc disease.

More articles on biologics:
NanoFUSE Biologics to crack Panama market — 3 things to know
Orthofix names DePuy, Medtronic, Biomet veteran the next CEO

Camber Spine delves into biologics with portfolio expansion

© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers